Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000997

Drug Information
NameIdoxuridine
Synonyms1-(4-Hydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-5-iodo-1H-pyrimidine-2,4-dione; Idu Oculos; KST-1B5615; HERPLEX (TN); Iducher; 5-IUDR; Prestwick1_000018; Prestwick2_000018; 1-[(2R,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; CHEMBL55681; Dendrid (TN); HMS1568C17; I0258; ZINC17779640; I7125_SIAL; CID6093284; AC1L32PJ; 1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 5-(125-I)-Iodo-2-deoxyuridine; ZINC13547843; CID5905; 2'-Deoxy-5-iodouridine; Uracil, 5-iodo-1-(2-deoxy-beta-D-ribofuranosyl)-; 1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 4-24-00-01235 (Beilstein Handbook Reference); Idoxene; CID6419973; Uridine, 5-iodo-2'-deoxy-; Herplex liquifilm; 5-Iododeoxyuridine; SMR001330614; AC1LAD5A; EU-0051633; CID6604188; I01-1120; Antizona; Idoxuridine (JP15/USP/INN); URIDINE, 2'-DEOXY-5-IODO-; Prestwick0_000018; Herpe-Gel; 5-I-2'-dUrd; CHEBI:100594; NSC39661; Idoxuridin; 5IdU; SPBio_001976; IDU; Spectanefran; HMS664F22; Ophthalmadine; Idoxuridinum [INN-Latin]; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; Allergan 201; Herpid; Oftan-IDU; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; EINECS 200-207-8; 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; NSC-39661; Idossuridina [DCIT]; Uridine, 2'-deoxy-5-(iodo-125I)-; MolPort-001-828-315; IdUrd; Iduoculos; Iodoxuridine; AI3-50861; C9H11IN2O5; SMP2_000072; 5-Iodo-2'-deoxyuridine; 2'-deoxy-5-(125i)iodouridine; Iododeoxyuridine; ZINC05223557; CID10021274; NCGC00016243-01; MolPort-002-700-148; ID2; Virudox; AB00674532-01; idoxuridine; CID3687; Stoxil; DB00249; Herpidu; Dendrid; Kerecid; SMR001233472; SKF 14287; AC1Q77TF; AC1LAEAG; ZINC03834173; CID1272916; MolPort-001-792-514; DB03778; Prestwick3_000018; UNII-LGP81V5245; Uracil, 5-iodo-1-(2-deoxy-.beta.-D-ribofuranosyl)-; AC1LOX7N; 2'-Deoxy-5-(iodo-125I)uridine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; BSPBio_000055; AC1O4WH8; 5-Iodouracil deoxyriboside; Idexur; 1-(2-deoxypentofuranosyl)-4-hydroxy-5-iodopyrimidin-2(1H)-one; Idoxuridinum; AC1Q4P64; ZINC00537850; 1-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; CHEMBL268690; Iododeoxyridine; Iduridin; Herpes-Gel; AC1Q1GNE; Herpesil; F1531-0025; LT00440811; MolPort-004-954-137; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 54-42-2; AR-1E1094; 60110-67-0; CHEBI:147675; CID512326; HMS2090M10; CHEMBL240359; Emanil; 1.beta.-D-2'-Deoxyribofuranosyl-5-iodouracil; Allergan 211; ChemDiv1_027236; AKOS003631534; A1555/0067734; CID511644; Oprea1_780054; STK673655; BPBio1_000061; nchembio.90-comp8; MLS002702846; Idoxuridine [USAN:INN:BAN:JAN]; SK&F 14287; AR-1E1122; AC1L45MB; 1336-77-2; AC1L1GHN; CID179629; Synmiol; 56061-30-4; Heratil; LS-160825; AC1L1LE0; Idoxuridina [INN-Spanish]; (+)-5-Iodo-2'-deoxyuridine; CID107764; CHEMBL408518; Herplex; ST041015; 1-(2-deoxypentofuranosyl)-5-iodopyrimidine-2,4(1h,3h)-dione; CID9884756; Idoxuridina; NCI60_003716; XQFRJNBWHJMXHO-UHFFFAOYSA-; MLS002154175; Allergan-211; Idulea; Idossuridina; AC1O1BNO; AC1O7GAI; CCRIS 2827; AR-1B0767; D00342; Iododeoxyuridine-125I; Joddeoxiuridin; 5-Iododesoxyuridine; HSDB 7479; CHEMBL788; AC1MHON1; 5IUDR; CID3008588; 53745-34-9; IDUR; ZINC02562618; SK&F-14287; NSC 39661; ZINC03586101; AC1Q7CC1; TL8003566; BRN 0030397; Kerecide; IUDR; CAS-54-42-2; Iduviran; NCGC00179673-01; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; I7125_SIGMA; Prestwick_523; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; WLN: T6NVMVJ EI A- ET5OTJ B1Q CQ
IndicationHerpes simplex virus infection
[ICD9: 054   ICD10: B00]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5
-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7?/m0/s1
InChIKeyXQFRJNBWHJMXHO-GFCOJPQKSA-N
Canonical SMILESC1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O    
Isomeric SMILESC1[C@@H]([C@H](OC1N2C=C(C(=O)NC2=O)I)CO)O
Therapeutic ClassAntiviral Agents
CAS NumberCAS 54-42-2
FormulaC9H11IN2O5
PubChem Compound IDCID 16051928.
PubChem Substance IDSID 24896108.
SuperDrug ATC IDD06BB01; J05AB02; S01AD01
SuperDrug CAS ID000054422;
TargetDNABinder[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 014169 To Reference
Ref 2Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543